Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

In consideration for the immediate exercise of the existing warrants for cash and the payment of $0.125 per new warrant, the Company issued new unregistered warrants to purchase up to an aggregate of 3,395,782 shares of Class A common stock. The new warrants are immediately exercisable at an exercise price of$2.50 per share and have a term of twenty-four months from the date of issuance. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. T ...